Darrin Disley

Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom.

Part of Roquefort Therapeutics Plc, Oncogeni Ltd. operates as a British biotechnology company. The private company is based in Stratford-upon-Avon, UK. The company was founded in 2019 by Nobel Laureate, Martin John Evans, Trevor Ajan Reginald. Oncogeni was acquired by Roquefort Therapeutics Plc on September 16, 2022 for $4.61 million.

Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom.

Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.

Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom.

Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.

Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.

Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom.